The Latest Breaking News from Gilead

Gilead Sciences (NASDAQ:GILD) announced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or…

A new U.N. AIDS agency report says the sudden withdrawal of U.S. funding has caused a “systemic shock” to the global effort against AIDS and HIV

Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

FDA approval paves the way for the jab to roll out across the world. But with funding being slashed, will it get to the people who need it? Rachel Schraer reports

US Congress member Marjorie Taylor Greene purchased shares of Adobe, Netflix, Snowflake, ServiceNow, NextEra Energy, and Gilead Sciences on 6th June.

It's unclear how many people in the US and abroad will get access to the powerful new HIV prevention medication

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.

A twice-yearly drug called lenacapavir is now the longest-lasting type of PrEP